Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network

被引：4

作者：

Ghesquieres, Herve ^{[1
]}

Houillier, Caroline ^{[2
,3
]}

Chinot, Olivier ^{[4
]}

Choquet, Sylvain ^{[3
,5
]}

Molucon-Chabrot, Cecile ^{[6
]}

Beauchene, Patrick ^{[7
]}

Gressin, Remy ^{[8
]}

Morschhauser, Franck ^{[9
]}

Schmitt, Anna ^{[10
]}

Gyan, Emmanuel ^{[11
]}

Hoang-Xuan, Khe ^{[2
,3
]}

Nicolas-Virelizier, Emmanuelle ^{[12
]}

Chevrier, Marion ^{[13
]}

Savignoni, Alexia ^{[13
]}

Turbiez, Isabelle ^{[14
]}

Veillas, Florence ^{[15
]}

Soumelis, Vassili ^{[16
,17
]}

Soussain, Carole ^{[18
]}

机构：

[1] Univ Claude Bernard, Hospices Civils Lyon, Ctr Hospitalier Lyon Sud, Pierre Benite, France

[2] Hop La Pitie Salpetriere, Neuro Oncol Dept, Paris, France

[3] Pierre & Marie Curie Univ, Paris, France

[4] Hop La Timone, Neuro Oncol, Marseille, France

[5] Hop La Pitie Salpetriere, Dept Clin Hematol, Paris, France

[6] CHU Clermont Ferrand, Dept Hematol, Clermont Ferrand, France

[7] CHU Nancy, Neuro Oncol, Nancy, France

[8] CHU Grenoble, Hematol, Grenoble, France

[9] Univ Lille, Dept Clin Hematol, Ctr Hospitalier Univ, Lille, France

[10] Inst Bergonie, Dept Hematol, Bordeaux, France

[11] Ctr Hospitalier Univ, Serv Hematol & Therapie Cellulaire, Tours, France

[12] Ctr Leon Berard, Hematol, Lyon, France

[13] Inst Curie, Biostatist Dept, St Cloud, France

[14] Inst Curie, Project Management, St Cloud, France

[15] Inst Curie, Data Management, St Cloud, France

[16] Inst Curie, Dept Clin Immunol, Paris, France

[17] Inst Curie, INSERM U 932, Paris, France

[18] Inst Curie, Dept Hematol, Hop Rene Huguenin, St Cloud, France

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.785.785

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

785

引用

页数：5

共 50 条

[21] Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib
Terui, Yasuhito
Narita, Yoshitaka
Nagane, Motoo
Mishima, Kazuhiko
Arakawa, Yoshiki
Yonezawa, Hajime
Asai, Katsunori
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
BLOOD, 2021, 138
[22] Intensive chemotherapy-followed by hematopoietic stem cell rescue for refractory or recurrent primary central nervous system (PCNSL) or intra ocular lymphoma (IOL). Results of a multicentric phase II study.
Soussain, Carole
Hoang-Xuan, Khe
Taillandier, Luc
Casasnovas, Olivier
Dupriez, Brigitte
Taksin, Anne-Laure
Souleau, Bertrand
Kolb, Brigitte
Jaccard, Arnaud
Zini, Jean-Marc
Choquet, Sylvain
Witz, Francis
Janvier, Maud
Leblond, Veronique
BLOOD, 2006, 108 (11) : 123A - 123A
[23] Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients (vol 17, pg 86, 2024)
Alcantara, Marion
Chevrier, Marion
Jardin, Fabrice
Schmitt, Anna
Houillier, Caroline
Oberic, Lucie
Chinot, Olivier
Morschhauser, Franck
Peyrade, Frederic
Houot, Roch
Hoang-Xuan, Khe
Ghesquieres, Herve
Soussain, Carole
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
[24] Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiaiton temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results
Glass, Jon
Won, Minhee
Schultz, Christopher J.
Brat, Daniel
Bartlett, Nancy
Suh, John H.
Fisher, Barbara Jean
Liepman, Marcia K.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[25] Phase II trial of high-dose intravenous methotrexate (MTX) and rituximab with or without intraventricular DepoCyt in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)
Fisher, Rebecca
Glantz, Michael
Blumenthal, Deborah
Batten, Julia
Van Horn, Alixis
Chalmers, Lisa
Chamberlain, Marc
NEURO-ONCOLOGY, 2006, 8 (04) : 441 - 441
[26] Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study
Bromberg, Jacoline
Issa, Samar
Bukanina, Katerina
Minnema, Monique C.
Seute, Tatjana
Durian, Marc
Cull, Gavin
Schouten, Harry C.
Stevens, Wendy B.
Zijlstra, Josee
Baars, Johanna W.
Nijland, Marcel
Mason, Kylie
Beeker, Aart
van den Bent, Martin
de Jong, Daphne
Gonzales, Michael Anthony
Doorduijn, Jeanette K.
BLOOD, 2017, 130
[27] EFFECT OF RITUXIMAB IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA - RESULTS OF THE RANDOMIZED PHASE III HOVON 105/ALLG NHL 24 STUDY
Bromberg, J. E. C.
Issa, S.
Bakunina, K.
Minnema, M. C.
Seute, T.
Cull, G.
van den Bent, M. J.
Gonzales, M.
de Jong, D.
Doorduijn, J. K.
NEURO-ONCOLOGY, 2018, 20 : 220 - 220
[28] Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy
Pels, H
Schmidt-Wolf, IGH
Glasmacher, A
Schulz, H
Engert, A
Diehl, V
Zellner, A
Schackert, G
Reichmann, H
Kroschinsky, F
Vogt-Schaden, M
Egerer, G
Bode, U
Schaller, C
Deckert, M
Fimmers, R
Helmstaedter, C
Atasoy, A
Klockgether, T
Schlegel, U
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4489 - 4495
[29] Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL)
Alcantara, Marion
Chevrier, Marion
Jardin, Fabrice
Schmitt, Anna
Houillier, Caroline
Oberic, Lucie
Chinot, Olivier L.
Morschhauser, Franck
Peyrade, Frederic
Houot, Roch
Foulon, Christine
Chauvin, Estelle
Ghesquieres, Herve
Soussain, Carole
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[30] Effect of Rituximab in Primary Central Nervous System Lymphoma-Results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 16 - 17

← 1 2 3 4 5 →